Abbott’s Continuous Glucose Monitoring Device Available in US Without a Prescription

Stock.adobe.com

Abbott’s continuous glucose monitoring system Lingo is available in the US. The device provide real-time data and with personal health and fitness advice, and will be available without the need of a prescription.

In a press release, Abbott divisional vice president of its Lingo business Olivier Ropars said, “There is a great deal of interest in tracking biomarkers that provide insights into one's health and wellness that were previously undetectable using the trackers available to consumers. Glucose is a powerful signal of your body's unique response to food and lifestyle. Abbott's Lingo tracks your glucose 24/7, translating the data into insights and bridging the gap between traditional healthcare and preventative measures. Lingo empowers individuals to build new healthy habits and take control of their health and wellness."

Cardiologist and medical director of El Camino Health Heart and Vascular Institute Fred St. Goar, MD, also commented, saying, “Physical activity and nutrition are two major factors that impact glucose variability and while glucose spikes are normal, fewer spikes and crashes are associated with numerous short-term and long-term health benefits. Understanding your body's glucose is key to managing your metabolism, so you can live healthier and better. CGMs are a powerful tool that I recommend to my patients to help them better understand what is going on inside their bodies, so they can take actional steps to improve mood, focus, energy, sleep, reduced cravings, and improve their health outcomes."

Abbott also recently announced that it is beginning clinical trials on the use of deep brain stimulation for the treatment of treatment-resistant depression.² FDA previously granted Abbott breakthrough device designation for its deep brain stimulation system.

In a press release, lead neurosurgery investigator and director of the Center for Neuromodulation Brian Kopell, MD, said, “As we have learned more about the intricacies of the brain, it is now clear that 'psychiatric diseases' like major depressive disorder are similar to other neurological conditions – we can see identifiable structural and functional changes in the brain. So, it is not surprising that deep brain stimulation research has demonstrated promise for people suffering with treatment-resistant depression, as it has for patients with medically complicated Parkinson's disease over the past two decades. We are eager for Abbott's TRANSCEND trial to gather further evidence about the impact neurostimulation could have for people who need different treatment options than are currently available."

Kopell is al the co-director of the Bonnie and Tom Strauss Center for Movement Disorders at Mount Sinai Health System.

In the same press release, Abbott’s vice president of neuromodulation Pedro Malha said, “Treatment-resistant depression is a debilitating condition affecting 2.8 million Americans each year. The goal of Abbott's TRANSCEND study, in collaboration with top clinical research centers, is to develop the clinical evidence necessary to determine whether DBS is a safe and effective treatment for treatment-resistant depression, which could provide people with a new treatment option that will allow them to live fuller lives."

Source

1. Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S. Abbott. September 5, 2024. https://www.prnewswire.com/news-releases/abbotts-lingo-continuous-glucose-monitor-for-health-and-wellness-now-available-in-the-us-302239097.html
2. Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression. Abbott. September 4, 2024. https://www.prnewswire.com/news-releases/abbott-initiates-clinical-study-to-evaluate-the-use-of-its-deep-brain-stimulation-system-to-manage-severe-depression-302237771.html